| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | PD-0332991 | FIMM | pan-cancer | AAC | 0.27 | 0.1 |
| mRNA | A-443654 | GDSC1000 | pan-cancer | AAC | -0.075 | 0.1 |
| mRNA | CEP-701 | GDSC1000 | pan-cancer | AAC | -0.049 | 0.1 |
| mRNA | BRD-K85133207 | CTRPv2 | pan-cancer | AAC | -0.053 | 0.1 |
| mRNA | tivozanib | CTRPv2 | pan-cancer | AAC | -0.052 | 0.1 |
| mRNA | decitabine | CTRPv2 | pan-cancer | AAC | -0.039 | 0.1 |
| mRNA | KIN001-102 | GDSC1000 | pan-cancer | AAC | -0.043 | 0.1 |
| mRNA | crizotinib:PLX-4032 (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.049 | 0.1 |
| mRNA | BRD-K66532283 | CTRPv2 | pan-cancer | AAC | -0.047 | 0.1 |
| mRNA | BRD-K45681478 | CTRPv2 | pan-cancer | AAC | 0.051 | 0.1 |